This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis, through a prospective, multicenter, randomized controlled clinical trial, starting 48 hours after endoscopic treatment to prevent rebleeding.
Clinical and imaging diagnosis of liver cirrhosis and esophagogastric varices, with at least one previous episode of esophagogastric variceal bleeding
Combined with portal vein thrombosis and D-dimer > 0.8mg/L
Endoscopic evaluation reveals a high risk of variceal bleeding, and endoscopic treatment is performed to prevent rebleeding of esophagogastric varices
Signed informed consent form
Received other antithrombotic therapies before (including warfarin, aspirin, low-molecular-weight heparin, etc.)
Combined with hepatocellular carcinoma or other malignancy
Combined with portal cavernoma
Combined with severe life-threatening diseases of circulatory, hematological and respiratory system